Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 95,497 Cr.
- Current Price ₹ 949
- High / Low ₹ 1,324 / 628
- Stock P/E 22.3
- Book Value ₹ 217
- Dividend Yield 0.32 %
- ROCE 22.3 %
- ROE 20.7 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 8.23% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty LargeMidcap 250 BSE Dollex 200 Nifty200 Alpha30 Nifty100 ESG Nifty 500 Multicap 50:25:25
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6,358 | 7,224 | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,547 | 21,484 | |
5,228 | 6,021 | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,013 | 11,768 | 13,378 | 14,163 | 15,205 | |
Operating Profit | 1,130 | 1,203 | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 | 5,384 | 6,278 |
OPM % | 18% | 17% | 20% | 25% | 20% | 24% | 23% | 20% | 24% | 22% | 22% | 28% | 29% |
32 | 30 | 45 | 112 | 127 | 111 | 183 | -264 | -231 | 2,581 | -422 | 293 | 351 | |
Interest | 169 | 90 | 68 | 53 | 45 | 91 | 194 | 342 | 159 | 127 | 130 | 81 | 112 |
Depreciation | 185 | 201 | 287 | 292 | 373 | 539 | 599 | 696 | 670 | 713 | 723 | 764 | 849 |
Profit before tax | 809 | 942 | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 | 4,832 | 5,668 |
Tax % | 15% | 11% | 18% | 8% | 8% | 24% | 22% | 21% | 8% | 10% | 23% | 20% | |
690 | 836 | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,439 | |
EPS in Rs | 6.38 | 7.85 | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 | 42.72 |
Dividend Payout % | 24% | 23% | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 11% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | 17% |
3 Years: | 18% |
TTM: | 37% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 30% |
3 Years: | 27% |
1 Year: | 48% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 20% |
3 Years: | 21% |
Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Reserves | 2,842 | 3,337 | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 21,724 |
2,918 | 2,700 | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,608 | 4,221 | 1,195 | 804 | 190 | |
1,512 | 1,847 | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,165 | 6,421 | 6,851 | 8,201 | 9,431 | |
Total Liabilities | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 31,446 |
3,026 | 3,124 | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,188 | 11,521 | 12,368 | 14,304 | |
CWIP | 736 | 892 | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 1,051 |
Investments | 114 | 87 | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,220 | 2,596 |
3,498 | 3,885 | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 12,822 | 13,495 | |
Total Assets | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 31,446 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
603 | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | 2,689 | 3,228 | |
-682 | -438 | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | |
286 | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,810 | |
Net Cash Flow | 207 | -64 | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 219 | -170 | -75 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 55 | 57 | 67 | 68 | 89 | 98 | 110 | 94 | 79 | 81 | 94 | 97 |
Inventory Days | 191 | 184 | 175 | 158 | 193 | 211 | 208 | 207 | 246 | 245 | 197 | 202 |
Days Payable | 103 | 123 | 125 | 154 | 165 | 167 | 149 | 152 | 168 | 141 | 123 | 125 |
Cash Conversion Cycle | 142 | 119 | 118 | 71 | 116 | 142 | 169 | 149 | 158 | 185 | 168 | 175 |
Working Capital Days | 63 | 46 | 56 | 46 | 62 | 95 | 99 | 79 | 95 | 112 | 95 | 103 |
ROCE % | 18% | 17% | 23% | 28% | 16% | 18% | 15% | 11% | 14% | 13% | 15% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19 Nov - Transcript of Q2 FY25 earnings call for Zydus Lifesciences.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Publication of unaudited financial results for Q2 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Nov - Audio recording of investor call available on website.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12 Nov - Zydus Lifesciences reports Q2 FY25 financial results.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
12 Nov - Investor presentation on Q2 FY25 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Mar 2020TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptPPT
-
Nov 2016Transcript PPT
-
May 2016Transcript PPT
Business Segments